Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells

European Respiratory Journal

Volumn 38, Issue 5, 2011, Pages 1117-1126

  Roulois, D ^a   Vignard, V ^a   Gueugnon, F ^a   Labarriere N ^a   Gregoire M ^a   Fonteneau, J F ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Cytotoxic T cells; Glycobiology; Immune response; Mesothelioma; Mucin 1

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MONOCLONAL ANTIBODY; MUCIN 1;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL CLONE; CELL SURFACE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN TARGETING;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CLONE CELLS; GLYCOSYLATION; HLA-A2 ANTIGEN; HUMANS; MESOTHELIOMA; MUCIN-1; PLEURAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80355138048     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00160210     Document Type: Article

References (43)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408. (Pubitemid 41073959)
2. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
3. Gregoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr 2010; 4: 153-161.
4. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 2001; 32: 197-201. (Pubitemid 32372611)
5. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982; 61: 1007-1009. (Pubitemid 12045175)
6. Anraku M, Cunningham KS, Yun Z, et al. Impact of tumour-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008; 135: 823-829. (Pubitemid 351417931)
7. Yamada N, Oizumi S, Kikuchi E, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010; 59: 1543-1549.
8. Gregoire M, Ligeza-Poisson C, Juge-Morineau N, et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: preclinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003; 21: 791-794. (Pubitemid 36091999)
9. Ebstein F, Sapede C, Royer PJ, et al. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am J Respir Crit Care Med 2004; 169: 1322-1330. (Pubitemid 39571861)
10. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010; 181: 1383-1390.
11. Yokokawa J, Palena C, Arlen P, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005; 11: 6342-6351. (Pubitemid 41262966)
12. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumour 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumour cells. Clin Cancer Res 2007; 13: 4547-4555. (Pubitemid 47219725)
13. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82: 249-293. (Pubitemid 38209513)
14. Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2010; 2: 305-327.
15. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159-7163. (Pubitemid 19240884)
16. Noto H, Takahashi T, Makiguchi Y, et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 1997; 9: 791-798. (Pubitemid 27226403)
17. Hinoda Y, Takahashi T, Hayashi T, et al. Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells. J Gastroenterol 1998; 33: 164-171. (Pubitemid 28143392)
18. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651. (Pubitemid 23059449)
19. Hiltbold EM, Alter MD, Ciborowski P, et al. Presentation of MUC1 tumour antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999; 194: 143-149. (Pubitemid 29340166)
20. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2- restricted T-cell epitopes derived from the MUC1 tumour antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309-4317. (Pubitemid 29279274)
21. Brossart P, Schneider A, Dill P, et al. The epithelial tumour antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001; 61: 6846-6850. (Pubitemid 32896509)
22. Tsang KY, Palena C, Gulley J, et al. A human cytotoxic Tlymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004; 10: 2139-2149. (Pubitemid 38375576)
23. Creaney J, Segal A, Sterrett G, et al. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 2008; 98: 1562-1569. (Pubitemid 351652333)
24. Gueugnon F, Leclercq S, Blanquart C, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 2011; 178: 1033-1042.
25. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986; 5: 943-949.
26. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumour-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001; 258: 111-126. (Pubitemid 33016531)
27. Davodeau F, Difilippantonio M, Roldan E, et al. The tight interallelic positional coincidence that distinguishes T-cell receptor Jα usage does not result from homologous chromosomal pairing during VαJα rearrangement. EMBO J 2001; 20: 4717-4729. (Pubitemid 32848625)
28. Arden B, Clark SP, Kabelitz D, et al. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500. (Pubitemid 26025063)
29. Cao Y, Karsten U. Binding patterns of 51 monoclonal antibodies to peptide and carbohydrate epitopes of the epithelial mucin (MUC1) on tissue sections of adenolymphomas of the parotid (Warthin's tumours): role of epitope masking by glycans. Histochem Cell Biol 2001; 115: 349-356. (Pubitemid 32323892)
30. Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J 2004; 382: 363-373. (Pubitemid 39141600)
31. Thathiah A, Blobel CP, Carson DD. Tumour necrosis factor- αconverting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 2003; 278: 3386-3394. (Pubitemid 36801254)
32. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumour by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 2001; 61: 6201-6212. (Pubitemid 32762558)
33. Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumour immune responses. Clin Cancer Res 2007; 13: 4456-4466. (Pubitemid 47219714)
34. Ali G, Boldrini L, Lucchi M, et al. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer 2009; 101: 1869-1875.
35. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83: 2099-2104. (Pubitemid 28525391)
36. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001; 31: 303-310. (Pubitemid 32107025)
37. Friedlander PL, Delaune CL, Abadie JM, et al. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 2003; 29: 321-330. (Pubitemid 37093990)
38. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25: 876-883. (Pubitemid 350002889)
39. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006; 8: R27.
40. Dreicer R, Stadler WM, Ahmann FR, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27: 379-386.
41. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12: 869-877. (Pubitemid 43259870)
42. North SA, Graham K, Bodnar D, et al. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006; 176: 91-95. (Pubitemid 43815368)
43. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008; 3: 735-744.